Cornerstone Advisors LLC Purchases 1,900 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cornerstone Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 31.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,900 shares of the biopharmaceutical company’s stock after purchasing an additional 1,900 shares during the period. Cornerstone Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $5,627,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Amundi grew its holdings in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Proficio Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after purchasing an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $127,489,000. KBC Group NV increased its holdings in Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after purchasing an additional 102,198 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $65,180,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Finally, Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Up 5.3 %

REGN stock opened at $744.83 on Tuesday. The firm has a market capitalization of $81.43 billion, a PE ratio of 19.46, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The stock’s 50 day moving average is $696.96 and its 200-day moving average is $845.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the business earned $11.86 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.